PL3512850T3 - Inhibitory interakcji menina-mll - Google Patents

Inhibitory interakcji menina-mll

Info

Publication number
PL3512850T3
PL3512850T3 PL17772585.0T PL17772585T PL3512850T3 PL 3512850 T3 PL3512850 T3 PL 3512850T3 PL 17772585 T PL17772585 T PL 17772585T PL 3512850 T3 PL3512850 T3 PL 3512850T3
Authority
PL
Poland
Prior art keywords
menin
inhibitors
mll interaction
mll
interaction
Prior art date
Application number
PL17772585.0T
Other languages
English (en)
Inventor
Salvacion Cacatian
David A. Claremon
Chengguo DONG
Yi Fan
Lanqi Jia
Stephen D. Lotesta
Suresh B. Singh
Shankar Venkatraman
Jing Yuan
Yajun Zheng
Linghang Zhuang
Original Assignee
Vitae Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals, Llc filed Critical Vitae Pharmaceuticals, Llc
Publication of PL3512850T3 publication Critical patent/PL3512850T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17772585.0T 2016-09-16 2017-09-15 Inhibitory interakcji menina-mll PL3512850T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16
PCT/US2017/051780 WO2018053267A1 (en) 2016-09-16 2017-09-15 Inhibitors of the menin-mll interaction

Publications (1)

Publication Number Publication Date
PL3512850T3 true PL3512850T3 (pl) 2023-10-09

Family

ID=59966892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17772585.0T PL3512850T3 (pl) 2016-09-16 2017-09-15 Inhibitory interakcji menina-mll

Country Status (15)

Country Link
US (3) US10899758B2 (pl)
EP (2) EP3512850B1 (pl)
JP (3) JP2019529421A (pl)
KR (1) KR102536029B1 (pl)
CN (3) CN118359610A (pl)
AR (1) AR109658A1 (pl)
AU (1) AU2017326006B2 (pl)
DK (1) DK3512850T3 (pl)
ES (1) ES2948949T3 (pl)
FI (1) FI3512850T3 (pl)
IL (2) IL295972A (pl)
MX (2) MX2019003091A (pl)
PL (1) PL3512850T3 (pl)
TW (1) TWI757340B (pl)
WO (1) WO2018053267A1 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11447484B2 (en) * 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
CN114981270B (zh) * 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
US12559487B2 (en) * 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) * 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20250000799A1 (en) * 2021-11-11 2025-01-02 V-Ensure Pharma Technologies Private Limited Reconstitutable, Single Use Antidiabetic Compositions
JP2025513798A (ja) * 2022-04-08 2025-04-30 ヤンセン ファーマシューティカ エヌ.ベー. メニン/mll相互作用の阻害剤の結晶質形態
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
JP2025540762A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及びbcl-2阻害剤を含む組み合わせ
EP4626885A1 (en) * 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Cyclobutyl substituted bicyclic compounds
JP2025540759A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及び少なくとも1つの他の治療剤を含む組み合わせ
WO2024114658A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
KR20260115654A (ko) * 2023-12-04 2026-07-24 쇼우야오 홀딩스 (베이징) 코., 엘티디. 치환된 다환 화합물
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts
WO2026158355A1 (zh) * 2025-01-22 2026-07-30 首药控股(北京)股份有限公司 取代的多环化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US8940725B2 (en) * 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6327713B2 (ja) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂

Also Published As

Publication number Publication date
US11739085B2 (en) 2023-08-29
WO2018053267A1 (en) 2018-03-22
KR102536029B1 (ko) 2023-05-23
KR20190111008A (ko) 2019-10-01
US10899758B2 (en) 2021-01-26
AU2017326006A1 (en) 2019-03-21
JP2025022910A (ja) 2025-02-14
IL265028B (en) 2022-09-01
EP3512850A1 (en) 2019-07-24
US20240124447A1 (en) 2024-04-18
RU2019111169A (ru) 2020-10-20
MX2019003091A (es) 2019-07-08
BR112019005030A2 (pt) 2019-06-18
IL265028A (pl) 2019-04-30
TWI757340B (zh) 2022-03-11
CN118359610A (zh) 2024-07-19
ES2948949T3 (es) 2023-09-22
EP4230627A3 (en) 2023-11-15
FI3512850T3 (fi) 2023-06-20
EP3512850B1 (en) 2023-04-12
NZ751049A (en) 2025-05-02
CN110325533B (zh) 2025-11-04
RU2019111169A3 (pl) 2020-12-30
TW201825486A (zh) 2018-07-16
AR109658A1 (es) 2019-01-09
AU2017326006B2 (en) 2021-10-28
CN121735946A (zh) 2026-03-27
JP2019529421A (ja) 2019-10-17
US20210179611A1 (en) 2021-06-17
DK3512850T3 (da) 2023-07-03
MX2022013841A (es) 2022-11-30
IL295972A (en) 2022-10-01
JP2022189853A (ja) 2022-12-22
CA3036987A1 (en) 2018-03-22
US20190202830A1 (en) 2019-07-04
CN110325533A (zh) 2019-10-11
EP4230627A2 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
IL321844A (en) Menin–MLL interaction inhibitors
IL259560A (en) Inhibitors of the menin-mll interaction
IL287113A (en) smyd inhibitors
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
AU364417S (en) Back of the case
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201513481D0 (en) Inhibitor compounds
GB201403536D0 (en) Inhibitor compounds
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201505658D0 (en) Inhibitor compounds
GB201612860D0 (en) Inhibitors
GB201501004D0 (en) Inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL262111A (en) Monovalent inhibitors of hutnfr1 interaction
GB201403558D0 (en) Coating
GB201520949D0 (en) Inhibitors
GB201401005D0 (en) Inhibitor
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201621619D0 (en) Inhibitor compounds
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
GB201522453D0 (en) Inhibitor compounds